|
Rudi Pauwels (born 1960) is a Belgian pharmacologist. He studied pharmaceutical sciences at the Catholic University of Leuven, Belgium, and obtained a PhD with a dissertation on ''Development of New Anti-HIV Agents''. He did research on virology at the Rega Institute for Medical Research .〔Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, et al., Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives, Nature. 1990 Feb 1;343(6257):470-4〕 In 1994 he founded the Belgian biotech company Tibotec, together with his wife Carine Claeys, and in 1995 he co-founded Virco. At Tibotec he continued his work on HIV.〔Vingerhoets J., Azijn H., Fransen E., De Baere I., Smeulders L., Jochmans D., Andries K., Pauwels R., de Béthune M-P., TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments, Journal of virology 2005;79(20):12773-82〕 In 1999, he was elected as board member of the Flemish Institute for Biotechnology (VIB). Rudi Pauwels is also the co-founder, director and CEO of a molecular diagnostic company, Biocartis SA, based in Parc Scientifique EPFL, Lausanne, Switzerland. ==References== 〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Rudi Pauwels」の詳細全文を読む スポンサード リンク
|